AU2020396807A1 - Treatment for acute myeloid leukemia or myelodysplastic syndrome - Google Patents

Treatment for acute myeloid leukemia or myelodysplastic syndrome Download PDF

Info

Publication number
AU2020396807A1
AU2020396807A1 AU2020396807A AU2020396807A AU2020396807A1 AU 2020396807 A1 AU2020396807 A1 AU 2020396807A1 AU 2020396807 A AU2020396807 A AU 2020396807A AU 2020396807 A AU2020396807 A AU 2020396807A AU 2020396807 A1 AU2020396807 A1 AU 2020396807A1
Authority
AU
Australia
Prior art keywords
compound
myeloid leukemia
lymphoma
leukemia
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020396807A
Other languages
English (en)
Inventor
Mark R. Bray
Graham Fletcher
Jacqueline M. Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of AU2020396807A1 publication Critical patent/AU2020396807A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020396807A 2019-12-06 2020-12-04 Treatment for acute myeloid leukemia or myelodysplastic syndrome Pending AU2020396807A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944876P 2019-12-06 2019-12-06
US62/944,876 2019-12-06
PCT/CA2020/051668 WO2021108918A1 (en) 2019-12-06 2020-12-04 Treatment for acute myeloid leukemia or myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
AU2020396807A1 true AU2020396807A1 (en) 2022-07-21

Family

ID=76221282

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020396807A Pending AU2020396807A1 (en) 2019-12-06 2020-12-04 Treatment for acute myeloid leukemia or myelodysplastic syndrome

Country Status (12)

Country Link
US (1) US12533357B2 (https=)
EP (1) EP4069246A4 (https=)
JP (1) JP2023505301A (https=)
KR (1) KR20220124177A (https=)
CN (1) CN115397429A (https=)
AU (1) AU2020396807A1 (https=)
BR (1) BR112022011052A2 (https=)
CA (1) CA3163796A1 (https=)
IL (1) IL293623A (https=)
MX (1) MX2022006910A (https=)
TW (1) TWI880995B (https=)
WO (1) WO2021108918A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
JP7717842B2 (ja) 2021-05-11 2025-08-04 オリック ファーマシューティカルズ，インク． ポロ様キナーゼ４阻害剤
US20250049787A1 (en) * 2021-12-22 2025-02-13 University Health Network Treatment for acute myeloid leukemia or lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
SI2556071T1 (sl) * 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
ES2706066T3 (es) * 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2015051304A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions, biomarkers and their use in treatment of cancer
HUE043194T2 (hu) * 2013-10-18 2019-08-28 Univ Health Network PLK-4 inhibitor sója és kristályformái
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
JP6617208B2 (ja) 2017-03-31 2019-12-11 ノバルティス アーゲー 血液腫瘍におけるｈｄｍ２−ｐ５３相互作用阻害剤の用量およびレジメン
WO2019046949A1 (en) * 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE
EP3720560A4 (en) * 2017-12-06 2022-01-05 Ludwig Institute for Cancer Research Ltd METHOD OF TREATMENT OF CANCER WITH PLK4 INHIBITORS

Also Published As

Publication number Publication date
CN115397429A (zh) 2022-11-25
US12533357B2 (en) 2026-01-27
WO2021108918A1 (en) 2021-06-10
CA3163796A1 (en) 2021-06-10
MX2022006910A (es) 2022-11-09
TWI880995B (zh) 2025-04-21
KR20220124177A (ko) 2022-09-13
BR112022011052A2 (pt) 2022-08-16
EP4069246A4 (en) 2023-12-06
EP4069246A1 (en) 2022-10-12
TW202134237A (zh) 2021-09-16
JP2023505301A (ja) 2023-02-08
IL293623A (en) 2022-08-01
US20230010772A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
US20120295864A1 (en) Method for treating acute myeloid leukemia
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
US12533357B2 (en) Treatment for acute myeloid leukemia or myelodysplastic syndrome
WO2010081817A1 (en) Method for treating colorectal cancer
WO2013184621A1 (en) Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
JP2023529365A (ja) 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ
TWI849001B (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
US20230132982A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
CN113509475A (zh) Bcl-2/bcl-xl抑制剂的组合及相关用途
CA3245251A1 (en) TREATMENT METHOD COMPRISING KRAS G12C INHIBITORS AND SHP2 INHIBITORS
EA049792B1 (ru) Лечение острого миелоидного лейкоза или миелодиспластического синдрома
IL300145A (en) A combination of a BCL-2 inhibitor and a hypomethylating agent for the treatment of cancer, its uses and pharmaceutical preparations
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
CN121285550A (zh) 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途
AU2014264318B2 (en) Combination of a PI3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck
CN117042771A (zh) 使用serd给药方案的组合治疗癌症的方法
CN120227387A (zh) 含三氟甲基化合物和化疗药物的组合用于治疗血液肿瘤